ABNM Nuclear Medicine

Practice session

A 60-year-old man with mCRPC has received second-line enzalutamide and taxane chemotherapy and has PSMA-positive disease on Ga-68 PSMA-11 PET without dominant PSMA-negative lesions. What is the FDA-approved Pluvicto regimen?

Loading your practice session…